Evotec’s multi-target collaboration with Bayer HealthCare has reached an important milestone, transitioning an undisclosed molecule into preclinical development for the treatment of endometriosis. Financial details were not disclosed.   Under the October 2012 agreement, the companies aim to develop three clinical candidates within a five-year term. Both parties contribute drug targets and technology infrastructures and share the responsibility for early research and preclinical characterization ...